共 57 条
[11]
Braunwald E(2016)Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation J Am Heart Assoc 5 331-1258
[12]
January CT(2010)Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale Am Heart J 159 3083-2436
[13]
Wann LS(2009)Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples Stat Med 28 1242-1127
[14]
Calkins H(2014)The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments Stat Med 33 2427-424
[15]
Alexander KP(2019)Long-term relationship between atrial fibrillation, multimorbidity and oral anticoagulant drug use Mayo Clin Proc 94 607528-153
[16]
Brouwer MA(2021)Clustering and healthcare costs with multiple chronic conditions in a US study Front Public Health 8 1116-414
[17]
Mulder H(2018)Real-world comparative effectiveness, safety, and health care costs of oral anticoagulants in nonvalvular atrial fibrillation patients in the US department of defense population J Manag Care Spec Pharm 24 411-165
[18]
Chen MA(2021)Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients with active cancer JACC CardioOncol 3 147-undefined
[19]
Jani BD(2018)Effect of renal function on dosing of non-vitamin K antagonist direct oral anticoagulants among patients with nonvalvular atrial fibrillation Ann Pharmacother 52 405-undefined
[20]
Nicholl BI(2021)Effectiveness and safety of oral anticoagulants among non-valvular atrial fibrillation patients with polypharmacy Eur Heart J Cardiovasc Pharmacother 7 157-undefined